News
-
Australian pharma company De Motu Cordis (DMC), which is developing an epinephrine DPI for the treatment of anaphylaxis, announced that it has contracted with Catalent for product assembly, expanding a November 2022 deal with the… Read more . . .
-
The FDA has issued a complete response letter to Orexo’s NDA for OX124 intranasal dry powder naloxone for the reversal of opioid overdose, the company said. Orexo resubmitted the NDA in September 2023 after the… Read more . . .
-
According to NeOnc Technologies, the FDA has approved an expansion of an ongoing Phase 2a trial of the company’s NEO100 intranasal perillyl alcohol to include patients with recurrent grade 3 astrocytoma with isocitrate dehydrogenase 1… Read more . . .
-
Particle characterization specialist Micromeritics Instrument Corporation is set to be acquired by Spectris subsidiary Malvern Panalytical, the companies have announced. According to Spectris, the deal includes a $630 million payment up front and up to… Read more . . .
-
CDMO Kindeva Drug Delivery announced the completion of an FDA inspection at the company’s new laboratory facility in Woodbury, MN, USA and said that the site will continue with routine cGMP audits in the future.… Read more . . .
-
UTMB researchers publish preclinical data on intranasal mAb to prevent Tau accumulation in the brain
The University of Texas Medical Branch announced publication of an article in Science Translational Medicine by UTMB researchers who are developing an intranasal toxic tau conformation–specific monoclonal antibody-2 (TTCM2) to prevent the accumulation of tau protein… Read more . . .
-
FluGen announced that it has published data from a 2022 Phase 1 trial of its M2SR intranasal flu vaccine coadministered with Fluzone high dose intramuscular inactivated influenza vaccine (IIV) in people aged 65 to 85… Read more . . .
-
Merz Therapeutics announced that it has acquired Inbrija inhaled dry powder levodopa from Acorda Therapeutics, which declared bankruptcy earlier this year. Merz had served as a “stalking horse bidder” for the Acorda assets, which also… Read more . . .
-
Vistagen announced that it has been granted patents related to the use of PH80 pherine nasal spray for the treatment of migraine in Australia, Hong Kong, Japan, and Mexico. All four of the new patents… Read more . . .
-
Nocion Therapeutics, whose taplucainium (NTX-1175) DPI is in Phase 2 development for the treatment of chronic cough, has announced the appointments of two former Bellus Health executives, naming Catherine Bonuccelli to the scientific advisory board… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden